In-111 ibritumomab scintigraphy (planar and SPECT) and FDG PET/CT before Y-90 ibritumomab treatment in a patient with mantle cell lymphoma.

Author(s): Jimenez-Bonilla JF, Quirce R, Banzo I, Martinez-Rodriguez I, Sainz-Esteban A, Barragan JE, Lopez-Cordovilla JJ, Carril JM

Affiliation(s): Nuclear Medicine Service, Hospital Universitario Marques de Valdecilla, Universidad de Cantabria, Santander, Spain. jjimenez@humv.es

Publication date & source: 2007-12, Clin Nucl Med., 32(12):952-3.

Publication type: Case Reports

We report the case of a 75-year-old man, in whom Y-90 ibritumomab was requested because of relapse of blastoid variant mantle cell lymphoma diagnosed in 1995. Before Y-90 ibritumomab treatment, FDG PET and In-111 ibritumomab scintigraphy with planar views at 24 hours, 48 hours, and 5 days, including SPECT, were performed. Discordant information between both examinations was observed as, in addition to the lesions detected by In-111 ibritumomab imaging, FDG PET detected lesions that did not take up the ibritumomab. The discrepancy shown by both radiotracers has to be kept in mind before planning treatment with Y-90 ibritumomab, and for the correct evaluation of treatment response.